.

BioCryst Pharmaceuticals | BCRX

BioCryst Pharmaceuticals traded at $12.60 this Friday September 30th, increasing $0.24 or 1.94 percent since the previous trading session. Looking back, over the last four weeks, BioCryst Pharmaceuticals gained 9.35 percent. Over the last 12 months, its price fell by 8.23 percent. Looking ahead, we forecast BioCryst Pharmaceuticals to be priced at 11.99 by the end of this quarter and at 10.95 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
12.60
Daily Change
1.94%
Yearly
-8.23%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Chugai Pharma 3,626.00 -4.00 -0.11% -11.69%
Daiichi Sankyo 4,042.00 12.00 0.30% 37.11%
Alnylam Pharmaceuticals 200.16 -9.23 -4.41% 3.88%
BioCryst Pharmaceuticals 12.60 0.24 1.94% -8.23%
ChemoCentryx 51.66 0 0% 181.07%
DBV Technologies 1.77 -0.04 -2.21% -62.97%
Enanta Pharmaceuticals 51.87 -0.55 -1.05% -14.91%
Gilead Sciences 61.69 -1.38 -2.19% -10.02%
GlaxoSmithKline 1,305.80 -10.00 -0.76% -5.76%
Glaxosmithkline 29.43 0.07 0.24% -22.82%
Incyte Corp 66.64 0.03 0.05% -2.30%
Ionis Pharmaceuticals 44.23 -0.05 -0.11% 31.75%
Intra Cellular Therapies 46.53 1.28 2.83% 20.98%
Karyopharm Therapeutics 5.46 0.09 1.68% -7.46%
Mirati Therapeutics 69.84 -0.14 -0.20% -60.03%
Neurocrine Biosciences 106.21 3.45 3.36% 4.68%
Novavax 18.20 -0.37 -1.99% -89.98%
PTC Therapeutics 50.20 -0.15 -0.30% 33.05%
Ultragenyx Pharmaceutical 41.41 0.86 2.12% -52.84%
Regeneron Pharmaceuticals 688.87 -2.95 -0.43% 20.69%
Roche Holding 323.45 3.20 1.00% -6.31%
Sarepta Therapeutics 110.54 0.91 0.83% 15.09%
Vertex Pharmaceuticals 289.54 -3.26 -1.11% 60.54%

Indexes Price Day Year
USND 10576 -161.89 -1.51% -27.40%
US2000 1665 -10.21 -0.61% -25.74%

BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.